Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 10.73 USD -3.07%
Market Cap: 577.6m USD

Prothena Corporation PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Prothena Corporation PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Operating Income
-$222.2m
CAGR 3-Years
-11%
CAGR 5-Years
-16%
CAGR 10-Years
-12%
Alkermes Plc
NASDAQ:ALKS
Operating Income
$358.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Operating Income
-$28.7m
CAGR 3-Years
16%
CAGR 5-Years
-6%
CAGR 10-Years
12%
M
Mural Oncology PLC
NASDAQ:MURA
Operating Income
-$138.3m
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
577.6m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
7.7 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Operating Income?
Operating Income
-222.2m USD

Based on the financial report for Sep 30, 2025, Prothena Corporation PLC's Operating Income amounts to -222.2m USD.

What is Prothena Corporation PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-12%

Over the last year, the Operating Income growth was -32%. The average annual Operating Income growth rates for Prothena Corporation PLC have been -11% over the past three years , -16% over the past five years , and -12% over the past ten years .

Back to Top